Retatrutide appears to be a new treatment in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By stimulating these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ultimately contributes to significant reduction in body mass. While